Showing 2191-2200 of 4162 results for "".
- Top-line Phase 3 Data Promising for Galderma's RelabotulinumtoxinAhttps://modernaesthetics.com/news/top-line-phase-3-data-promising-for-galdermas-relabotulinumtoxina/2473250/Galderma’s investigational RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A, improves both glabellar and lateral canthal lines with a rapid onset of action and a long duration up to six months, according to top-line phase 3 data presen
- Cynosure Rolls Out PicoSure Pro Devicehttps://modernaesthetics.com/news/cynosure-rolls-out-picosure-pro-device/2473248/Cynosure is launching the PicoSure Pro device, the latest upgrade to the company's PicoSure system. The FDA-cleared 755nm picosecond laser on the market, the PicoSure Pro device uniquely delivers energy in a trillionth of a second, utilizing pressure instead of heat to provide
- IT Cosmetics Launches Confidence at Work Initiativehttps://modernaesthetics.com/news/it-cosmetics-launches-confidence-at-work-initiative/2473247/IT Cosmetics is launching Confidence at Work, an initiative that aims to bring awareness to the confidence crisis affecting women at work. The Founder of The American Confidence Institute, Alyssa Dver, will serve as the brand's official Confidence Educator.
- Merz Aesthetics Partners with North Carolina Courage, Reigning NWSL Challenge Cup Championshttps://modernaesthetics.com/news/merz-aesthetics-partners-with-north-carolina-courage-reigning-nwsl-challenge-cup-champions/2473240/In a new partnership with the North Carolina Courage, reigning NWSL Challenge Cup Champions and two-time champions of the National Women’s Soccer League (NWSL), Merz Aesthetics aims to promote confidence, character, and sportsmanship. The partnership, kicking off Sunday, includes
- Cynosure Receives $60 Million Follow-on Investment from Clayton, Dubilier & Ricehttps://modernaesthetics.com/news/cynosure-recieves-60-million-follow-on-investment-from-clayton-dubilier-rice/2473237/Cynosure, LLC, received $60 million from lead investor Clayton, Dubilier & Rice. The new capital supports the company's plans to continue investing ahead of strong growth to bring innovation to the market and provide comprehensive treatment solutions to its cust
- Colorescience, Aesthetics Biomedical Join Forces for New Collabhttps://modernaesthetics.com/news/colorescience-aesthetics-biomedical-join-forces-for-new-collab/2473229/Colorescience and Aesthetics Biomedical are launching a collaboration that combines Vivace Microneedle RF with a post-treatment protocol featuring Colorescience’s Sunforgettable Total Protection Brush-On Shield SPF 50. Patients opting for the radiofrequency microneedlin
- Revance News: FDA Accepts BLA Resubmission for DaxibotulinumtoxinAhttps://modernaesthetics.com/news/revance-news-fda-accepts-bla-resubmission-for-daxibotulinumtoxina/2473223/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont
- Cynosure and Jeisys Medical Japan Expand Partnershiphttps://modernaesthetics.com/news/cynosure-and-jeisys-medical-japan-expand-partnership/2473209/Cynosure LLC’s subsidiary Cynosure KK has entered into a distribution partnership with Jeisys Medical KK, a subsidiary of Jeisys Medical Inc. in Japan. Under the terms of the agreement, Jeisys Medical will have exclusive distribution rights for products within Cynosure&
- Alastin Receives Two New Patents for Technology Related to TransFORM Body Treatmenthttps://modernaesthetics.com/news/alastin-receives-two-new-patents-for-technology-related-to-transform-body-treatment/2473148/With the issuance of two new patents from the United States Patent and Trademark Office, Alastin Skincare, Inc. now holds six patents in the US, along with a seventh patent issued in Canada. US Patent No.11,052,032 covers Alastin’s
- Galderma's Restylane Turns 25!https://modernaesthetics.com/news/galdermas-restylane-turns-25/2473147/Galderma’s Restylane is celebrating 25 years on the market. Since launching in Europe in 1996, Restylane has celebrated many milestones across the globe. This includes the first approval for use by the U.S. Food and Drug Administration (FDA) in 2003 and in China by the Nation